報價延遲最少15分鐘:2026/04/22 23:57 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.48 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.48/-1.22
|
|
企業價值
78.30M
|
| 資產負債 |
|
每股賬面淨值
1.96
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals. |
